IP Library Patent Application 18196227
Patent Application
App. No. 18/196,227

SYSTEMS AND METHODS OF ANALYZING MICROBIOMES USING ARTIFICIAL INTELLIGENCE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/196,227
Abstract

Disclosed systems and methods include executing a convolutional neural network to detect a level of microbiome in a whole slide image associated with a patient, based on an output of the convolutional neural network, categorize the whole slide image as one of microbiome-low and microbiome-high, and, based on the categorization of the whole slide image, determine a characteristic of a cancer associated with the patient.

Claims (35)

1 . A computer system for assessing a patient's response to a cancer treatment wherein the patient has cancer, the system comprising:

a processor; and

a computer-readable storage medium storing computer-readable instructions which, when executed by a processor, cause the processor to:

execute a convolutional neural network to detect a level of microbiome in a whole slide image associated with the patient;

based on an output of the convolutional neural network, categorize the whole slide image as one of microbiome-low and microbiome-high; and

based on the categorization of the whole slide image, determine a characteristic of cancer associated with the patient.

2 . The system of claim 1 , wherein the whole slide image comprises hematoxylin and eosin (H&E)-stained pathology slides.

3 . The system of claim 1 , wherein the cancer is bladder cancer.

4 . The system of claim 3 , wherein the convolutional neural network is trained based on Formalin-Fixed Paraffin-Embedded (FFPE) diagnostic images sourced from a bladder cohort.

5 . The system of claim 1 , wherein the output of the convolutional neural network is used to determine a survival statistic of the patient.

6 . The system of claim 1 , wherein microbiome-low is associated with a microbiome level of less than a median microbiome level of a cohort and microbiome-high is associated with a microbiome level of greater than the median microbiome level of the cohort.

7 . The system of claim 1 , wherein the instructions further cause the processor to:

determine if the patient is responding to the cancer treatment based on the categorization of the whole slide image; and

continue treating the patient with the cancer treatment in response to determining the patient is responding to the cancer treatment.

8 . The system of claim 1 , wherein the instructions further cause the processor to determine a pathologic complete response (pCR) based on the output of the convolutional neural network.

9 . A method of assessing a patient's response to a cancer treatment wherein the patient has cancer, the method comprising:

executing a convolutional neural network to detect a level of microbiome in a whole slide image associated with the patient;

based on an output of the convolutional neural network, categorizing the whole slide image as one of microbiome-low and microbiome-high;

based on the categorization of the whole slide image, determining a characteristic of cancer associated with the patient;

determining the patient is responding to the cancer treatment based on the categorization of the whole slide image; and

continuing treating the patient with the cancer treatment in response to determining the patient is responding to the cancer treatment.

10 . The method of claim 9 , wherein the whole slide image comprises hematoxylin and eosin (H&E)-stained pathology slides.

11 . The method of claim 9 , wherein the cancer is bladder cancer.

12 . The method of claim 11 , wherein the convolutional neural network is trained based on Formalin-Fixed Paraffin-Embedded (FFPE) diagnostic images sourced from a bladder cohort.

13 . The method of claim 9 , wherein the output of the convolutional neural network is used to determine a patient survival statistic.

14 . The method of claim 9 , wherein microbiome-low is associated with a microbiome level of less than a median microbiome level of a cohort and microbiome-high is associated with a microbiome level of greater than the median microbiome level of the cohort.

15 . The method of claim 9 , further comprising determining a pathologic complete response (pCR) based on the output of the convolutional neural network.

16 . At least one machine-readable non-transitory medium comprising a plurality of instructions, executed on a computing device, to facilitate the computing device to:

execute a convolutional neural network to detect a level of microbiome in a whole slide image associated with a patient;

based on an output of the convolutional neural network, categorize the whole slide image as one of microbiome-low and microbiome-high; and

based on the categorization of the whole slide image, determine a characteristic of cancer associated with the patient.

17 . The machine-readable non-transitory medium of claim 16 , wherein the whole slide image comprises hematoxylin and eosin (H&E)-stained pathology slides.

18 . The machine-readable non-transitory medium of claim 16 , wherein the cancer is bladder cancer.

19 . The machine-readable non-transitory medium of claim 18 , wherein the convolutional neural network is trained based on Formalin-Fixed Paraffin-Embedded (FFPE) diagnostic images sourced from a bladder cohort.

20 . The machine-readable non-transitory medium of claim 16 , wherein the output of the convolutional neural network is used to determine a survival statistic of the patient.

Assignments (7)
SECURITY INTEREST Recorded Jan 2, 2024
From: IMMUNITYBIO, INC.; NANTCELL, INC.; RECEPTOME, INC.; VBC HOLDINGS LLC; ALTOR BIOSCIENCE, LLC; ETUBICS CORPORATION; IGDRASOL, INC.
To: INFINITY SA LLC, AS PURCHASER AGENT
Reel/Frame 066179/0074 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2023
From: REDDY, SANDIP
To: IMMUNITYBIO, INC.
Reel/Frame 063617/0595 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2023
From: WNUK, KAMIL
To: NANTHEALTH, INC.
Reel/Frame 063617/0690 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2023
From: JABER, MUSTAFA I.
To: NANTOMICS, LLC
Reel/Frame 063617/0552 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2023
From: IMMUNITYBIO, INC.
To: NANTCELL, INC.
Reel/Frame 063617/0751 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2023
From: NANTHEALTH, INC.
To: NANTCELL, INC.
Reel/Frame 063630/0825 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2023
From: NANTOMICS, LLC
To: NANTCELL, INC.
Reel/Frame 063617/0722 →